TP53 and cancer: Although targeted therapy and immunotherapy combinations have been successful in other cancer types, MCC has been infrequently included within targeted therapy basket trials.22 These results reveal that targeted therapies may be effective in select patients with variants in commonly altered pathways, including the TP53, cell cycle, PI3KA, and RTK-RAS pathways.